# RECURSION PHARMACEUTICALS, INC. (RXRX) FY2026 Q2 Balance Sheet

- Company: RECURSION PHARMACEUTICALS, INC. (RXRX)
- Period: As of 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-05, accession number 0001601830-26-000098
- Page: https://plicit.ai/financials/rxrx/fy2026-q2-balance-sheet
- Chart image: https://plicit.ai/charts/rxrx-fy2026-q2-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 1,212,668,000 US dollars
- **Current assets**: 603,462,000 US dollars
- **Non-current assets**: 609,206,000 US dollars
- **Liabilities**: 297,665,000 US dollars
- **Current liabilities**: 119,886,000 US dollars
- **Non-current liabilities**: 177,779,000 US dollars
- **Equity**: 915,003,000 US dollars
- **Cash and cash equivalents**: 545,683,000 US dollars
- **Other current assets**: 29,321,000 US dollars
- **Other receivables**: 14,393,000 US dollars
- **Prepaid data assets**: 8,680,000 US dollars
- **Restricted cash**: 5,385,000 US dollars
- **Intangible assets, net**: 282,888,000 US dollars
- **Goodwill**: 160,350,000 US dollars
- **Property and equipment, net**: 89,623,000 US dollars
- **Operating lease right-of-use assets**: 40,271,000 US dollars
- **Financing lease right-of-use assets**: 17,179,000 US dollars
- **Other assets, non-current**: 12,186,000 US dollars
- **Restricted cash, non-current**: 5,752,000 US dollars
- **Deferred tax assets**: 957,000 US dollars
- **Accrued expenses and other liabilities**: 56,936,000 US dollars
- **Unearned revenue**: 27,586,000 US dollars
- **Operating lease liabilities**: 13,249,000 US dollars
- **Accounts payable**: 12,672,000 US dollars
- **Notes payable and financing lease liabilities**: 9,443,000 US dollars
- **Unearned revenue, non-current**: 112,818,000 US dollars
- **Operating lease liabilities, non-current**: 39,193,000 US dollars
- **Deferred tax liabilities**: 18,313,000 US dollars
- **Notes payable and financing lease liabilities, non-current**: 4,753,000 US dollars
- **Other liabilities, non-current**: 2,702,000 US dollars
- **Additional paid-in capital**: 3,211,515,000 US dollars
- **Accumulated other comprehensive income**: 27,994,000 US dollars
- **Common stock, $0.00001 par value; 2,000,000,000 shares (Class A 1,989,032,117 and Class B 10,967,883) authorized as of June 30, 2026 and December 31, 2025; 534,120,235 shares (Class A 533,191,318, Class B — and Exchangeable 928,917) and 528,182,693 shares (Class A 521,831,046, Class B 5,547,334 and Exchangeable 804,313) issued and outstanding as of June 30, 2026 and December 31, 2025, respectively**: 5,000 US dollars
- **Accumulated deficit**: negative 2,324,511,000 US dollars
- **Gross equity (calculated)**: 3,239,514,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.